DK1264599T3 - TNF-afledte peptider til anvendelse i behandling af ödem - Google Patents

TNF-afledte peptider til anvendelse i behandling af ödem

Info

Publication number
DK1264599T3
DK1264599T3 DK02077256T DK02077256T DK1264599T3 DK 1264599 T3 DK1264599 T3 DK 1264599T3 DK 02077256 T DK02077256 T DK 02077256T DK 02077256 T DK02077256 T DK 02077256T DK 1264599 T3 DK1264599 T3 DK 1264599T3
Authority
DK
Denmark
Prior art keywords
tnf
alpha
present
oedema
edema
Prior art date
Application number
DK02077256T
Other languages
Danish (da)
English (en)
Inventor
Baetselier Patrick De
Rudolf Lucas
Jerome Pugin
Alain Bloc
Lucie Fransen
Original Assignee
Rudolf Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Lucas filed Critical Rudolf Lucas
Application granted granted Critical
Publication of DK1264599T3 publication Critical patent/DK1264599T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02077256T 1998-08-14 1999-08-10 TNF-afledte peptider til anvendelse i behandling af ödem DK1264599T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21
PCT/EP1999/005806 WO2000009149A1 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Publications (1)

Publication Number Publication Date
DK1264599T3 true DK1264599T3 (da) 2008-02-04

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02077256T DK1264599T3 (da) 1998-08-14 1999-08-10 TNF-afledte peptider til anvendelse i behandling af ödem

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1105152A1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69938743D1 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
CN105188735A (zh) * 2013-04-23 2015-12-23 阿佩普蒂科研究和开发有限责任公司 包含式x1-gqretpegaeakpwy-x2的环肽的药物组合物及其体外处理肺的用途
CA2940351A1 (en) 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére

Also Published As

Publication number Publication date
CZ2001538A3 (cs) 2001-08-15
HK1051805A1 (en) 2003-08-22
CN1181886C (zh) 2004-12-29
EP1105152A1 (en) 2001-06-13
EP1264599A1 (en) 2002-12-11
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
WO2000009149A1 (en) 2000-02-24
DE69937206D1 (de) 2007-11-08
IL141064A (en) 2009-09-01
EP1247531B1 (en) 2008-05-14
PL345997A1 (en) 2002-01-14
ATE374039T1 (de) 2007-10-15
US7258861B2 (en) 2007-08-21
ZA200100656B (en) 2005-06-29
HU227661B1 (hu) 2011-10-28
ATE395072T1 (de) 2008-05-15
JP4542266B2 (ja) 2010-09-08
ES2296872T3 (es) 2008-05-01
EP1264599B1 (en) 2007-09-26
BR9912899A (pt) 2001-05-08
CA2334941C (en) 2011-08-09
PL203706B1 (pl) 2009-11-30
NZ509604A (en) 2003-05-30
JP2002522508A (ja) 2002-07-23
AU5620999A (en) 2000-03-06
TR200100338T2 (tr) 2001-12-21
EP1247531A3 (en) 2002-12-18
IL141064A0 (en) 2002-02-10
CZ302862B6 (cs) 2011-12-21
DE69937206T2 (de) 2008-06-19
EP1247531A2 (en) 2002-10-09
DE69938743D1 (de) 2008-06-26
CA2334941A1 (en) 2000-02-24
HUP0103117A2 (hu) 2001-12-28
US20030105021A1 (en) 2003-06-05
AU764992B2 (en) 2003-09-04
PT1264599E (pt) 2008-01-07
CN1312724A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
DE69938743D1 (de) TNF-Peptide zur Behandlung von Ödemen
IL161591A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DK0397420T3 (da) Enzymatisk fjernelse af en aminoterminal proteinsekvens
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
NO20012787D0 (no) GLP-1 analoger
DE69922819D1 (de) Methode zur prävention und behandlung von dehnungsstreifen (striae distensae) und deren verwendung in dermatologie
NO20012786L (no) Analoger av GLP-1
EA199900355A1 (ru) Теломераза обратная тринскриптаза
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EA200201214A1 (ru) Замещенные тиоацетамиды
EP0873754A4 (en) AMINO ACID COMPOSITIONS
ATE350396T1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
AR037778A1 (es) Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ATE198987T1 (de) Behandlung von tropikalischer spastischer paresis mit peptide t
DE602004016834D1 (de) Zusammensetzung zur vermeidung und behandlung von cellulitis
ATE342352T1 (de) Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
DE60104695D1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
MXPA02012030A (es) Sustratos peptidicos de metalorpoteasas y metodos.
DE50006409D1 (de) Injektionslösung enthaltend eine goldverbindung, calendula und belladonna extrakte zur behandlung von arthrosen
DE602006017806D1 (de) Behandlung von neurodegeneration
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen